Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inhaled insulin, new perspective for insulin therapy].

R P Radermecker1, J L Sélam

  • 1Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Sart Tilman, 4000 Liège, Belgique. Regis.Radermecker@ulg.ac.be

Revue Medicale De Liege
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[When HbA1c is unreliable : a case report of hereditary spherocytosis].

Revue medicale de Liege·2022
Same author

[Nasal glucagon (Baqsimi®), new treatment for hypoglycaemic coma].

Revue medicale de Liege·2022
Same author

[Covid-19 and diabetes].

Revue medicale de Liege·2020
Same author

[Therapeutic and technological advances in the management of adult patients with type 1 diabetes].

Revue medicale de Liege·2020
Same author

[Pathologies of the musculoskeletal system in diabetes mellitus].

Revue medicale de Liege·2019
Same author

[Contribution of FreeStyle Libre® in the care of diabetic patients : experience at the CHU of Liege].

Revue medicale de Liege·2018
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Inhaled insulin offers a potential alternative to subcutaneous injections for diabetes management, improving patient compliance. Further research is needed on efficacy, safety, and cost-effectiveness compared to newer insulin analogues.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Pulmonary Medicine

Context:

  • Subcutaneous insulin injections are the standard for diabetes care.
  • Patient reluctance and compliance issues often hinder effective insulin therapy.
  • Alternative insulin delivery methods are actively being explored to improve patient outcomes.

Purpose:

  • To review different insulin pulmonary delivery devices.
  • To compare preliminary data of inhaled insulin versus subcutaneous injections.
  • To identify challenges and future research directions for inhaled insulin therapy.

Summary:

  • Inhaled insulin presents a promising alternative to traditional subcutaneous injections, potentially enhancing patient compliance and treatment intensification.
  • Various pulmonary delivery devices are under investigation, with preliminary data suggesting comparability to human regular insulin.

Related Experiment Videos

  • Key challenges include identifying effective bioavailability enhancers, addressing cost concerns, and conducting rigorous long-term safety studies, particularly regarding pulmonary toxicity.

    • Impact:

    • Inhaled insulin could significantly improve the quality of life for individuals with diabetes by offering a less invasive administration route.
    • Successful development may lead to wider adoption of intensified insulin therapies, improving glycemic control.
    • Ongoing research and pharmaceutical investment highlight the significant potential of inhaled insulin in diabetes care.